<DOC>
	<DOCNO>NCT01078441</DOCNO>
	<brief_summary>This phase II trial study well give bortezomib together liposomal doxorubicin hydrochloride , dexamethasone , cyclophosphamide work treat patient multiple myeloma relapse autologous stem cell transplant . Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , liposomal doxorubicin hydrochloride , dexamethasone , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib together liposomal doxorubicin hydrochloride , dexamethasone , cyclophosphamide may kill cancer cell .</brief_summary>
	<brief_title>Bortezomib , Liposomal Doxorubicin Hydrochloride , Dexamethasone , Cyclophosphamide Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate 1-year survival patient relapse multiple myeloma treat bortezomib , liposomal doxorubicin , dexamethasone , cyclophosphamide . SECONDARY OBJECTIVES : I . To evaluate response rate patient treated regimen . II . To evaluate median time progression patient treat regimen . III . To evaluate toxicity regimen patient . OUTLINE : This multicenter study . Patients receive bortezomib 1.3 mg/m2 subcutaneously day 1 , 8 , 15 ; liposomal doxorubicin 30 mg/m2 intravenously ( IV ) 1 hour day 4 ; oral dexamethasone 20mg day 1 , 2 , 8 , 9 , 15 16 ; cyclophosphamide 750 mg/m2 IV 2 hour day 1 . Treatment repeat every 21 day 12 cycle absence disease progression unacceptable toxicity . Peripheral blood bone marrow sample may collect future research . Patients complete Functional Assessment Cancer Therapy ( FACT ) neurotoxicity questionnaire periodically . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis multiple myeloma symptomatic time initial diagnosis Must meet follow criterion one point disease course : Bone marrow plasmacytosis ≥ 10 % plasma cell sheet plasma cell biopsyproven plasmacytoma Symptomatic disease initial diagnosis prompt initiation therapy well evidence endorgan damage time diagnosis , include least 1 follow : Anemia Hypercalcemia Bone disease ( lytic bone lesion pathologic fracture ) Renal dysfunction Disease relapse &lt; 12 month autologous stem cell transplantation ( SCT ) Measurable disease , define presence ≥ 1 following : Serum Mspike ≥ 1 g/dL Urine Mspike ≥ 200 mg/24 hour Involved free light chain ( FLC ) ≥ 10 mg/dL ( provide serum FLC abnormal ) Plasma cell ≥ 30 % ECOG performance status 02 Negative pregnancy test Fertile patient must use effective contraception At least 14 day since prior palliative and/or localize radiotherapy Left ventricular ejection fraction ( LVEF ) normal Echocardiography ( ECHO ) multiplegated acquisition ( MUGA ) scan Hemoglobin &gt; 8 g/dL Platelet count ≥ 75,000/mm^3 ( without transfusion support ) Absolute neutrophil count ( ANC ) ≥ 1,000/mm^3 ( without use growth factor ) Creatinine &lt; 2.5 mg/dL Direct bilirubin ≤ 1.5 mg/dL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time upper limit normal All test must perform within 14 day prior registration : Serum free light chain assay Kappa free light chain Lambda free light chain Prior malignancy allow provide treat curatively relapse 5 year Patients basal cell skin cancer , situ cervical cancer , prostate cancer require therapy eligible Therapy relapse disease follow SCT Known allergy bortezomib anthracyclines Prior allogeneic SCT Peripheral neuropathy ≥ grade 2 accord Cancer Therapy Evaluation Program ( CTEP ) active version NCI Common Terminology Criteria Adverse Events ( CTCAE ) Concurrent uncontrolled illness would limit study compliance , include follow : Uncontrolled hypertension Symptomatic congestive heart failure Unstable angina Uncontrolled cardiac arrhythmia Uncontrolled psychiatric illness social situation Active uncontrolled infection Prior doxorubicin hydrochloride exposure &gt; 240 mg/m^2 Active , uncontrolled seizure disorder Seizures within past 6 month Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Bortezomib</keyword>
	<keyword>Liposomal Doxorubicin</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>